We invite you to join us at the following events during the upcoming AABB Annual Meeting in San Antonio

Quick links:
Cerus Industry Workshop | Cerus' Exhibit Booth 
Pathogen Reduction presentations by topic: Orals | Posters: Platelets | Plasma | Red Blood Cells

Industry Workshop on Sunday October 20, 2019

AABB2019web header
Click image to download the invitation (90kb pdf)

Are You Ready for FDA’s Bacterial Contamination Guidance?

Sunday Oct 20, 2019
Room 214A/B
Henry B Gonzalez Convention Center
Breakfast will be served. No RSVP is required.

Program Description:*

Despite underreporting of transfusion-related sepsis, recent cases published by CDC (MMWR) and the general media have highlighted concerns. Upon finalization of FDA’s guidance on bacterial contamination, it is likely that both blood center and hospital institutions will have a defined period in which to ensure implementation of a method to address platelet transfusion safety. This workshop provides a pragmatic perspective on mitigating bacterial contamination risk with pathogen reduction. Topics will include a review of transfusion-associated sepsis cases, as well as the implementation of transfusion-ready pathogen reduced products at US hospitals.
  • Introduction - Safeguarding the World’s Blood Supply
    Dr. Andreas Buser, MD - Chair
    Regional Blood Transfusion Service, Swiss Red Cross, Basel, Switzerland

  • Why Should My Blood Center Consider Pathogen Reduction?
    Dr. Rita Reik, MD, FCAP
    Chief Medical Officer
    OneBlood, Inc., Florida, United States

  • Implementing Transfusion-Ready INTERCEPT Platelets in a US Hospital Setting
    Scott Hammel
    Supervisor - Component Laboratory, Division of Transfusion Medicine
    Department of Laboratory Medicine and Pathology
    Mayo Clinic, Minnesota, United States

  • Increasing PRT Platelet Availability for Patient Safety and FDA Compliance
    Dr. Patricia Kopko, MD
    Director of Transfusion Medicine
    University of California San Diego, California, United States
* The content of this industry workshop event was developed independently from the official continuing education program at the 2019 Annual Meeting. AABB does not provide continuing education (CE) or continuing medical education (CME) credit for these educational activities. Opinions expressed during these events are those of the faculty and are not necessarily a reflection of AABB’s opinions, nor are they supported, sponsored or endorsed by AABB.

Pathogen Reduction Oral and Poster Presentations

Posters and Orals describing experiences with the INTERCEPT Blood System will be presented at AABB.
For a full list of abstracts presented at AABB, including those below, please visit the AABB Program listing here

Oral Presentations:

  • A Rationale for Collecting Pathogen Reduction–Treated (PRT) Platelets Despite Malaria Risk Travel  (Scott, Mayo, OA5-ST2-16)
    Saturday, October 19, 2019, 11:00 AM - 11:15 AM, Room 302

  • Pathogen-Reduced Platelets Reduce Septic Transfusion Reactions Compared to Conventional Platelets – Despite Point of Release Testing (Bahar, Yale, OA4-SN5-37)
    Sunday, October 20, 2019, 04:45 PM - 05:00 PM, Room 302

  • Acute Zika Virus Infection in an Asymptomatic Blood Donor at the Onset of the Puerto Rico Epidemic (Saa, OA1-MN2-15)
    Monday, October 21, 2019, 10:30 AM - 10:45 AM, Room 30

  • Achieving 100% Pathogen Reduced Platelet Component Inventory with Production Optimization and Variable Dosing (Chrebtow, OA3-TU3-25)
    Tuesday, October 22, 2019, 11:30 AM - 11:45 AM, Room 301

  • Five Years of Routine Experience using Amotosalen/UVA-treated Platelets with Storage up to 7 Days (Infanti, OA4-TU3-25)
    Tuesday, October 22, 2019, 11:45 AM - 12:00 PM, Room 301

  • Sepsis from an apheresis platelet contaminated with A. baumannii and S. saprophyticus after pathogen reduction (Fridey, OA5-TU3-25)
    Tuesday, October 22, 2019, 12:00 PM - 12:15 PM, Room 301


On Display During Exhibition Hours: Henry B Gonzalez Convention Center


  • Implementation Of Amotosalen/UVA Pathogen Reduction System To improve Platelet Transfusion Safety In Honduras (Arriaga, P-BB-21)

  • Affordability of INTERCEPT Pathogen Reduction in Brazil: The Experience at HemoRio (Amorim, P-BB-31)

  • Amotosalen/UVA Treatment Inactivates Acinetobacter baumannii and Staphylococcus saprophyticus in Apheresis Platelet Concentrates In 65% PAS/35% Plasma to the Limit of Detection After 7 days of Storage (Lu, P-BB-11)


  • The Impact of Plasma Pooling and Pathogen Reduction on the Coagulation Factor Content of Human Plasma (Bubinski, P-BB-65)


  • Inactivation of Bacteria in AS-5 Red Blood Cell Components Treated with the INTERCEPT Blood System and Stored 35 Days (Lu, P-NE-6)1

  • Evaluation of the INTERCEPT RBC processing set with AS-1 storage solution (Schott, P-BB-25)1
1) The INTERCEPT Blood System for Red Blood Cells is in development and is not approved for sale. 

Cerus Booth

Please stop by and visit us at the Cerus /INTERCEPT Booth #1133, located in the main AABB Exhibition hall.